Beta Bionics, Inc. (NASDAQ:BBNX) CFO Sells $26,781.33 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) CFO Stephen Feider sold 1,497 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $26,781.33. Following the sale, the chief financial officer now directly owns 45,503 shares of the company's stock, valued at approximately $814,048.67. The trade was a 3.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Beta Bionics Stock Performance

Shares of Beta Bionics stock traded down $0.47 on Friday, hitting $19.08. 583,609 shares of the company's stock traded hands, compared to its average volume of 503,190. The firm has a 50-day moving average price of $13.05. Beta Bionics, Inc. has a one year low of $8.89 and a one year high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BBNX shares. Wolfe Research started coverage on shares of Beta Bionics in a research report on Friday, May 30th. They issued an "outperform" rating and a $20.00 price objective for the company. Robert W. Baird started coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price objective for the company. Baird R W upgraded shares of Beta Bionics to a "hold" rating in a research report on Thursday, February 20th. Leerink Partners started coverage on shares of Beta Bionics in a research report on Monday, February 24th. They issued an "outperform" rating and a $28.00 price objective for the company. Finally, The Goldman Sachs Group started coverage on shares of Beta Bionics in a research report on Friday, May 30th. They issued a "neutral" rating and a $16.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $23.13.

Institutional Trading of Beta Bionics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio acquired a new position in shares of Beta Bionics in the 1st quarter valued at $29,000. Corebridge Financial Inc. bought a new stake in shares of Beta Bionics in the 1st quarter valued at about $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Beta Bionics in the 1st quarter valued at about $95,000. MetLife Investment Management LLC bought a new stake in shares of Beta Bionics in the 1st quarter valued at about $102,000. Finally, Deutsche Bank AG bought a new stake in shares of Beta Bionics in the 1st quarter valued at about $148,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.